Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2008074997) PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS
Latest bibliographic data on file with the International Bureau   
Pub. No.: WO/2008/074997 International Application No.: PCT/GB2007/004800
Publication Date: 26.06.2008 International Filing Date: 14.12.2007
IPC:
C07D 213/74 (2006.01) ,C07D 241/12 (2006.01) ,C07D 241/20 (2006.01) ,C07D 401/04 (2006.01) ,C07D 405/04 (2006.01) ,C07D 409/04 (2006.01) ,A61K 31/44 (2006.01) ,A61K 31/4965 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
213
Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02
having three double bonds between ring members or between ring members and non-ring members
04
having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
72
Nitrogen atoms
74
Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
241
Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
02
not condensed with other rings
10
having three double bonds between ring members or between ring members and non-ring members
12
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
241
Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
02
not condensed with other rings
10
having three double bonds between ring members or between ring members and non-ring members
14
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
20
Nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965
Non-condensed pyrazines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
RAYNHAM, Tony, Michael [GB/GB]; GB (UsOnly)
HAMMONDS, Timothy, Robin [GB/GB]; GB (UsOnly)
CHARLES, Mark, David [GB/GB]; GB (UsOnly)
PAVÉ, Grégoire, Alexandre [FR/GB]; GB (UsOnly)
FOXTON, Caroline, Heather [GB/GB]; GB (UsOnly)
BLACKABY, Wesley, Peter [GB/GB]; GB (UsOnly)
STEVENS, Adrian, Philip [GB/GB]; GB (UsOnly)
EKWURU, Chukuemeka, Tennyson [GB/GB]; GB (UsOnly)
CANCER RESEARCH TECHNOLOGY LIMITED [GB/GB]; Sardinia House Sardinia Street London Greater London WC2A 3NL, GB (AllExceptUS)
Inventors:
RAYNHAM, Tony, Michael; GB
HAMMONDS, Timothy, Robin; GB
CHARLES, Mark, David; GB
PAVÉ, Grégoire, Alexandre; GB
FOXTON, Caroline, Heather; GB
BLACKABY, Wesley, Peter; GB
STEVENS, Adrian, Philip; GB
EKWURU, Chukuemeka, Tennyson; GB
Agent:
WYTENBURG, Wilhelmus ; Mewburn Ellis LLP 33 Gutter Lane London EC2V 8AS, GB
Priority Data:
0625659.821.12.2006GB
60/876,13921.12.2006US
Title (EN) PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS
(FR) BENZAMIDES DE PYRIDINE ET BENZAMIDES DE PYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PKD
Abstract:
(EN) The present invention pertains generally to the field of therapeutic compounds,. arid more specifically to certain pyridine benzamide and pyrazine benzamide compounds (I) (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD1 that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
(FR) La présente invention concerne en général le domaine des composés thérapeutiques, et plus spécifiquement certains composés benzamides de pyridine et benzamides de pyrazine (I) (désignés ici comme composés PDBA et PZBA) qui, entre autres, inhibent la protéine kinase D (PKD) (par exemple, la PKD1, la PKD2, la PKD3). La présente invention concerne également des compositions pharmaceutiques comprenant de tels composés, et l'utilisation de tels composés et compositions, à la fois in vitro et in vivo, pour inhiber la PKD, et dans le traitement de maladies et conditions qui sont induites par la PKD1 qui sont améliorées par l'inhibition de la PKD, etc., y compris des conditions prolifératives telles que le cancer, etc.
 front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)